Gout News and Research

Latest Gout News and Research

2010 GAPS sheds light on the painful reality of what life is like for gout patients

The 2010 Gout Attitudes Patient Survey, a new study of Americans with gout, released by Men's Health Network, sheds light on the painful reality of what life is like for the approximately five million Americans who live with this condition. Of those surveyed, 69 percent described the pain of a gout attack as "miserable," yet a quarter of gout patients feel that those without gout perceive them as overreacting to attacks, and 67 percent feel as though others do not take the condition seriously.

11 Jun 2010

Allopurinol exhibits potential benefits for CKD patients

A drug commonly used to treat gout may help maintain kidney disease patients' health, according to an analysis appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN). The research is the first to show that allopurinol treatment in patients with chronic kidney disease (CKD) decreases inflammation, slows the progression of kidney disease, and reduces patients' risk of experiencing a cardiovascular event or being hospitalized.

10 Jun 2010

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.

9 Jun 2010

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that two scientific abstracts on the activity of tranilast against key components of gout - high serum uric acid levels and monosodium urate crystal-induced inflammation - have been accepted for The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology, to be held in Rome, Italy, June 16-19, 2010.

4 Jun 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

BioCryst Pharmaceuticals, Inc. announced it is initiating a Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout. BioCryst recently reported positive results from part one of its Phase 2 monotherapy study of BCX4208 in patients with gout and is now moving forward as planned with an additional Phase 2 trial of BCX4208.

1 Jun 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Fibrocell Science commences histology study of azficel-T for treatment of nasolabial fold wrinkles

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced the initiation of a small histology study (IT-H-001) of azficel-T, an autologous cell therapy currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe nasolabial fold wrinkles.

14 May 2010

Chimerix commences first-in-human study of CMX157 for HIV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

14 May 2010

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Regeneron Pharmaceuticals, Inc. (REGN) provided an update on two antibody product candidates in its pipeline and scheduled its first Investor Day to be held in New York City on July 15, 2010. Both product candidates, REGN727 (SAR236553) and, REGN475 (SAR164877) are being developed with sanofi-aventis under a global, strategic collaboration to discover, develop, and commercialize fully human antibodies.

13 May 2010

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Ardea Biosciences, Inc. a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

7 May 2010

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

Savient Pharmaceuticals, Inc. announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA by the U.S. Food and Drug Administration (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders and other stakeholders.

6 May 2010

Tart cherries reduce osteoarthritis pain

Arthritis affects about one-quarter of Americans and has been called "the coming epidemic" by the Centers for Disease Control and Prevention. More than 67 million adults are expected to be afflicted by 2030. May is National Arthritis Month and experts like registered dietitian Dave Grotto want Americans to take a food-first approach to managing arthritis pain.

4 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

UCLA researchers show risks associated with heavy drinking among elderly adults

A new study by researchers at the David Geffen School of Medicine at UCLA has found that more than a third of drinkers 60 years old and older consume amounts of alcohol that are excessive or that are potentially harmful in combination with certain diseases they may have or medications they may be taking.

30 Apr 2010

REGN reports net loss of $30.5M for first-quarter 2010

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the first quarter of 2010. The Company reported a net loss of $30.5 million, or $0.38 per share (basic and diluted), for the first quarter of 2010 compared with a net loss of $15.4 million, or $0.19 per share (basic and diluted), for the first quarter of 2009.

30 Apr 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Higher the blood cholesterol level, greater the risk of atherosclerosis: Study

In addition to crystallized cholesterol, atherosclerotic plaques always contain large quantities of immune cells but, surprisingly, no bacteria or viruses. It was previously unclear just how the body's own defence forces are called into action. Even animals that are kept in an absolutely sterile environment can suffer from "clogging" or "furring" of the arteries when their food contains high levels of cholesterol.

29 Apr 2010

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

BioCryst Pharmaceuticals, Inc. announced positive top-line results from a planned interim analysis of its ongoing Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of orally administered BCX4208 in patients with gout.

28 Apr 2010

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that the company is advancing its lead program, NU1618, into phase 2b development for the treatment of chronic hyperuricemia in patients with gout. Nuon anticipates releasing topline data from a completed proof-of-principle, phase 2a study of NU1618 in the second quarter of 2010.

22 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

Gout News and Research

Latest Gout News and Research

2010 GAPS sheds light on the painful reality of what life is like for gout patients

Allopurinol exhibits potential benefits for CKD patients

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Nuon Therapeutics' abstracts on tranilast against gout accepted for presentation at EULAR 2010

BioCryst to commence Phase 2 study of BCX4208 alone and in combination with allopurinol in gout patients

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Fibrocell Science commences histology study of azficel-T for treatment of nasolabial fold wrinkles

Chimerix commences first-in-human study of CMX157 for HIV

Regeneron Pharmaceuticals provides update on REGN727, REGN475 antibody product candidates

Ardea Biosciences reports lower net loss of $10.1M for first-quarter 2010

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

Tart cherries reduce osteoarthritis pain

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

UCLA researchers show risks associated with heavy drinking among elderly adults

REGN reports net loss of $30.5M for first-quarter 2010

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Higher the blood cholesterol level, greater the risk of atherosclerosis: Study

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Nuon Therapeutics advances NU1618 into phase 2b development for chronic hyperuricemia in gout patients

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Gout News and Research

Latest Gout News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in